Noah Auerhahn's Podcasts

Welcome to our podcast, where we explore the latest and most intriguing developments in the biotech and pharmaceutical industries. Today, we're diving into the recent $925 million acquisition of Anthos Therapeutics by Novartis. We'll break down the deal, the science behind abelacimab, and the implications for the future of anticoagulant treatments.